Sodium Valproate-Induced Liver Injury

Itoh, Susumu; Yamaba, Yoshitaka; Matsuo, Shuichi; Saka, Masaharu; Ichinoe, Akira
November 1982
American Journal of Gastroenterology;Nov1982, Vol. 77 Issue 11, p875
Academic Journal
Centrilobular zonal necrosis developed in the liver of a 37-yr-old woman who had been taking sodium valproate for 1 month as prophylactic anticonvulsant medication after a cranioplasty. A challenge test was positive. Ultra-structurally, the hepatocytes revealed megamitochondria with crystalline inclusions, disorganized rough endoplasmic reticulum, and no increase in smooth endoplasmic reticulum. These findings suggest that cytotoxic liver injury was induced by sodium valproate in our patient.


Related Articles

  • Biochemical, Molecular and Epigenetic Mechanisms of Valproic Acid Neuroprotection. Monti, Barbara; Polazzi, Elisabetta; Contestabile, Antonio // Current Molecular Pharmacology;Jan2009, Vol. 2 Issue 1, p95 

    Valproic acid (VPA, 2-propylpentanoic acid) has been widely used as an antiepileptic drug and for the therapy of bipolar disorders for several years. Its mechanism of action was initially found to be primarily related to neurotransmission and modulation of intracellular pathways. More recently,...

  • Autism linked to valproic acid exposure in utero.  // Reactions Weekly;12/13/2008, Issue 1232, p2 

    The article discusses research being done on the association between autism spectrum disorders (ASD) and valproic acid exposure in utero. It references a study by R. L. Bromley and colleagues published in the December 2, 2008 issue of the journal "Neurology." Researchers found that 6.3 percent...

  • Efficacy Of Monotherapy With Carbamazepine And Valproic Acid In Patients With Bronchial Asthma: Is Asthma A Neurological Disease? Lomia, M. // Internet Journal of Urology;2005, Vol. 2 Issue 2, p9 

    Antiasthmatic activity of carbamazepine and sodium valproate was investigated in 28 patients (open-label trial) with moderate and severe bronchial asthma. Stable and complete remission was achieved in 10 patients of the carbamazepine group (n=14), and in 11 patients of the sodium valproate group...

  • Seizure Worsening Caused by Decreased Serum Valproate During Meropenem Therapy. Santucci, Margherita; Parmeggiani, Antonia; Riva, Roberto // Journal of Child Neurology;May2005, Vol. 20 Issue 5, p456 

    Serum concentrations of valproate were reduced and seizures were exacerbated by concomitant meropenem therapy in a child with a neurodegenerative disorder and epilepsy. In this patient, a rapid decline of valproate serum concentrations was observed on two occasions with meropenem antibiotic...

  • Epilim Chrono.  // Royal Society of Medicine: Medicines;2002, p230 

    The article presents information on Epilim Chrono, a proprietary, prescription-only preparation of the anticonvulsant and anti-epileptic sodium valproate. It can be used to treat epilepsy, and is available as modified-release tablets.

  • Epilim Intravenous.  // Royal Society of Medicine: Medicines;2002, p230 

    The article presents information on Epilim Intravenous, a proprietary, prescription-only preparation of the anticonvulsant and anti-epileptic sodium valproate. It can be used to treat epilepsy, and is available in a form for injection.

  • Vitamin U, a novel free radical scavenger, prevents lens injury in rats administered with valproic acid. Tunali, S.; Kahraman, S.; Yanardag, R. // Human & Experimental Toxicology;Sep2015, Vol. 34 Issue 9, p904 

    Valproic acid (2-propyl-pentanoic acid, VPA) is the most widely prescribed antiepileptic drug due to its ability to treat a broad spectrum of seizure types. VPA exhibits various side effects such as organ toxicity, teratogenicity, and visual disturbances. S-Methylmethioninesulfonium is a...

  • Valproic acid.  // Reactions Weekly;3/11/2006, Issue 1092, p26 

    Discusses research on encephalopathy and hyperammonaemia developed by a 48-year-old man during treatment with valproic acid for generalised tonic-clonic seizure disorder. Reference to a study by J. L. Lee et al published in the November-December 2005 issue of the "Journal of Pharmacy...

  • Valproate-Induced Liver Injury: Modulation by the Omega-3 Fatty Acid DHA Proposes a Novel Anticonvulsant Regimen. Abdel-Dayem, Marwa; Elmarakby, Ahmed; Abdel-Aziz, Azza; Pye, Chelsey; Said, Shehta; El-Mowafy, Abdalla // Drugs in R&D;Jun2014, Vol. 14 Issue 2, p85 

    Background: The polyunsaturated, ω-3 fatty acid, docosahexaenoic acid (DHA), claims diverse cytoprotective potentials, although via largely undefined triggers. Thus, we currently first tested the ability of DHA to ameliorate valproate (VPA)-evoked hepatotoxicity, to modulate its...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics